<DOC>
	<DOCNO>NCT01271777</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy insulin sensitivity GFT505 80mg/d male patient insulin resistance abdominal obesity . Evaluation make use glucose clamp technique .</brief_summary>
	<brief_title>Pilot Study With GFT505 ( 80mg ) Patients With Insulin Resistance Abdominal Obesity</brief_title>
	<detailed_description>The study period per patient 26 week : selection period precede 8-week treatment period , 6-week wash period , second 8-week treatment period second arm treatment 2- week follow-up period . Schedule : - Selection visit prior treatment period ( D-14 D-1 ) - D0 : randomisation visit - Period T1 : first period treatment GFT505 80mg placebo 8 week ( D1 D56 ) - Wash period 6 week ( D57 D98 ) - Period T2 : second period treatment GFT505 80mg placebo 8 week ( D99 D154 ) - Follow period 2 week ( D155 D169 )</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Obesity , Abdominal</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Waist circumference ≥94cm . Body Mass Index ≤ 45kg/m2 . Homeostasis Model Assessment Insulin Resistance ( HOMAIR ) &gt; 3 . Blood Pressure &gt; 160 / 95 mmHg . Diabetes mellitus 1 2 . Historical bariatric surgery . Patient treat lipiddecreasing medication . A fasting plasma triglyceride concentration &gt; 400mg/dL plasma Low Density Lipoprotein Cholesterol ( LDLc ) concentration &gt; 220mg/dL .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Pre-diabetes</keyword>
	<keyword>Clamp technique</keyword>
	<keyword>PPARs</keyword>
	<keyword>Insulin resistance</keyword>
</DOC>